Demand Soars For Parallel EMA-HTA Advice
This article was originally published in SRA
There has been a huge increase in use by drug companies of the scheme that enables them to get simultaneous feedback on their development plans for new medicines from the European Medicines Agency and national health technology assessment (HTA) bodies.
You may also be interested in...
The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.
New medicines under evaluation at the European Medicines Agency.